Improving the efficacy of antibody-based cancer therapies

被引：642
作者：
Carter, P [1 ]
机构：
[1] Immunex Corp, Seattle, WA 98101 USA
来源：
NATURE REVIEWS CANCER | 2001年 / 1卷 / 02期
关键词：
D O I：
10.1038/35101072
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A quarter of a century after their advent, monoclonal antibodies have become the most rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases, including cancer. Although antibodies have yet to achieve the ultimate goal of curing cancer, many innovative approaches stand poised to improve the efficacy of antibody-based therapies.
引用
收藏
页码：118 / 129
页数：12
相关论文
共 140 条
[1]  
Adams GP, 2001, CANCER RES, V61, P4750
[2]  
Adams GP, 1998, CANCER RES, V58, P485
[3]  
ADAMS GP, 1993, CANCER RES, V53, P4026
[4]   A potential role for activated HER-2 in prostate cancer [J].
Agus, DB ;
Akita, RW ;
Fox, WD ;
Lofgren, JA ;
Higgins, B ;
Maiese, K ;
Scher, HI ;
Sliwkowski, MX .
SEMINARS IN ONCOLOGY, 2000, 27 (06) :76-83
[5]  
Ajani JA, 2000, CANCER J, V6, P78
[6]  
BAKER TS, 1994, ANTIGEN ANTIBODY MOL
[7]   Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].
Baselga, J ;
Tripathy, D ;
Mendelsohn, J ;
Baughman, S ;
Benz, CC ;
Dantis, L ;
Sklarin, NT ;
Seidman, AD ;
Hudis, CA ;
Moore, J ;
Rosen, PP ;
Twaddell, T ;
Henderson, IC ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744
[8]  
Baselga J, 1998, CANCER RES, V58, P2825
[9]   Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library [J].
Begent, RHJ ;
Verhaar, MJ ;
Chester, KA ;
Casey, JL ;
Green, AJ ;
Napier, MP ;
HopeStone, LD ;
Cushen, N ;
Keep, PA ;
Johnson, CJ ;
Hawkins, RE ;
Hilson, AJW ;
Robson, L .
NATURE MEDICINE, 1996, 2 (09) :979-984
[10]   Immunoliposomes - A promising approach to targeting cancer therapy [J].
Bendas, G .
BIODRUGS, 2001, 15 (04) :215-224
12345678910